Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | NR4A2 | P43354 | 8/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.52 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.51 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.49 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23748620 | 1.00 | KMT2A (0.63) | KMT2ANR4A2NR1H4PLA2G4BNR4A1 | |
| SCHEMBL28826720 | 0.88 | MAOB (0.56) | KMT2A | |
| SCHEMBL29960206 | 0.86 | NR4A2 (0.56) | KMT2ANR4A2NR1H4NR4A1NR4A3 | |
| SCHEMBL10812101 | 0.86 | NR4A2 (0.60) | KMT2ANR4A2NR1H4PLA2G4BNR4A1 | |
| SCHEMBL202108 | 0.83 | PARP1 (0.51) | KMT2ACYSLTR1NPC1RAB9A | |
| SCHEMBL202107 | 0.83 | PARP1 (0.51) | KMT2ACYSLTR1NPC1RAB9A | |
| SCHEMBL17138220 | 0.82 | AOC3 (0.47) | GPBAR1CYSLTR1NPC1RAB9A | |
| SCHEMBL17138219 | 0.82 | AOC3 (0.47) | GPBAR1CYSLTR1NPC1RAB9A | |
| SCHEMBL23748660 | 0.81 | PLA2G4B (0.54) | NR4A2PLA2G4BNR4A1NR4A3NPC1 | |
| SCHEMBL23748627 | 0.81 | PLA2G4B (0.54) | NR4A2PLA2G4BNR4A1NR4A3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380521-A1 | AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | BASF AS (NO) | 2021-12-09 | — | — | US | disclosed |
| EP-3864001-A1 | ROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | BASF AS (NO) | 2021-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380521-A1 | AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | GLS2, FFAR3, SLC10A1 | KMT2A 2026/4885NR4A2 1537/4885NR1H4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.